{"filings":[{"id":93488,"accession_number":"0001104659-26-042362","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"DarioHealth appoints veteran healthcare exec John R. Palumbo to board to support commercial scaling","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John R. Palumbo, age 75, appointed to DarioHealth board effective April 10, 2026.","Brings over 40 years healthcare experience incl. senior roles at AmerisourceBergen and Allscripts.","Appointment aims to accelerate commercial scaling and channel partnerships per CEO Erez Raphael.","Also serves on boards of Lucid Diagnostics (LUCD), PM Pediatrics, ivWatch, and QLess.","Will receive standard non-executive director fees; no material transactions to disclose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105157,"accession_number":"0001104659-26-036834","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"DarioHealth enters $20M at-the-market equity distribution agreement with A.G.P./Alliance Global Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may issue and sell up to $20M of common stock through ATM program with A.G.P./Alliance Global Partners.","Commission of 3.00% of gross proceeds; reimbursement of expenses up to $35,000 plus quarterly fees.","Proceeds to be used for commercial activities, R&D, M&A, corporate activities, repayment of debt, and working capital.","Shares offered under effective S-3 registration statement filed March 19, 2026, effective March 27, 2026.","Company has no obligation to sell any shares and may suspend or terminate the agreement at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105156,"accession_number":"0001104659-26-009247","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"DarioHealth amends charter to allow board to alter bylaws; stockholder approval obtained Jan 29","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended charter filed Feb 2, 2026 authorizes board to alter/repeal bylaws, subject to stockholder power.","Stockholders approved the amendment at annual meeting on January 29, 2026.","Governance change does not affect financials, operations, or outstanding shares.","Exhibit 3.1 contains the full Amended and Restated Certificate of Incorporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105155,"accession_number":"0001104659-26-007974","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DarioHealth shareholders approve all seven proposals at 2026 Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors elected: Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Lawrence Leisure, Adam K. Stern.","Ratified Kesselman & Kesselman (PwC) as auditor for FY 2026 (4,952,777 for, 17,242 against).","Approved conversion of 25,605 Series D/D-1/D-2/D-3 preferred shares into 1,697,843 common shares, plus dividend and lock-up shares.","Ratified issuance of common shares upon exercise of pre-funded warrants, warrants and RSUs from Twill acquisition.","Approved increase in equity incentive plan by 500,000 shares and charter amendment allowing board to amend bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121413,"accession_number":"0001104659-25-109166","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"DarioHealth amends credit facility; resets covenants, waives Q2/Q3 tests, adds $10M liquidity covenant","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Credit agreement amended with Callodine Commercial Finance on Nov 5, 2025.","Financial covenant testing waived for Q2 and Q3 2025; minimum unencumbered liquid assets set at $10M.","Additional $2.5M funding from lenders now uncommitted and discretionary; exit fee increased by $150k.","Warrant exercise price reduced from $16.556 to $15.3495; conversion price on up to $2.5M loan reduced to $15.3495.","Amendment fee of $150k paid; 13-week cash-flow reporting required when liquidity below $11M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138079,"accession_number":"0001104659-25-093431","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"DarioHealth launches strategic review, raises $17.5M via private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board formed Special Committee, engaged Perella Weinberg as advisor to explore sale, merger, or standalone.","Raised $17.5M gross via private placement of 1.15M shares and 1.56M pre-funded warrants at $6.45/share.","Series C-1 Preferred mandatory conversion accelerated; holders receive common stock or pre-funded warrants plus dividends.","Offering closed September 23, 2025; net proceeds for general corporate purposes.","Strategic review follows multiple unsolicited inbound inquiries from interested parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138078,"accession_number":"0001104659-25-091718","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"DarioHealth accelerates mandatory conversion of Series C & D preferred stock into common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Sept 18, 2025: all outstanding Series C, C-2, D, D-1, D-2, D-3 preferred convert to common stock or pre-funded warrants at holder's election.","Series A-1 certificate amended to give holders option to receive pre-funded warrants instead of common stock on conversion.","Each holder also receives all accrued unpaid dividends, including PIK shares, subject to beneficial ownership blockers.","Amendments approved by majority of preferred holders and Board; no new securities issued or sold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138077,"accession_number":"0001104659-25-089629","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"DarioHealth regains Nasdaq minimum bid price compliance; deficiency closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Sep 12, 2025 confirming compliance with Rule 5550(a)(2).","Closing bid price at or above $1.00 for 10 consecutive days (Aug 28 to Sep 11, 2025).","The matter is now closed; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138076,"accession_number":"0001104659-25-082513","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"DarioHealth announces 20-for-1 reverse stock split effective August 28, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 20:1 ratio takes effect at market open on August 28, 2025.","Outstanding shares reduced from ~47,996,572 to ~2,399,829; authorized shares unchanged at 400M.","No fractional shares issued; fractional shares rounded up to nearest whole share.","Trading symbol DRIO unchanged; new CUSIP 23725P 308.","Proportional voting rights and dividends unaffected; options and warrants adjusted accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138075,"accession_number":"0001104659-25-070069","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DarioHealth shareholders authorize reverse stock split and increase in authorized shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with majority support; Hila Karah received the most 'against' votes (1.98M).","Kesselman & Kesselman (PwC) ratified as independent auditor for FY2025; 40.1M for, 146k against.","Amended 2020 Equity Compensation Plan approved; adds 6% annual share increase and authorizes RSU grants.","Reverse stock split (2:1 to 25:1) authorized; implementation by Sept 15, 2025, at Board's discretion.","Authorized common stock increased from 160M to 400M shares; approved by stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138074,"accession_number":"0001104659-25-066982","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DarioHealth appoints Steven M. Nelson as President, retains CCO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven M. Nelson, 52, appointed President effective July 10, 2025, in addition to serving as Chief Commercial Officer.","Nelson has been CCO since June 2024; prior President/CEO of Contigo Health and leadership roles at Elevance Health.","No changes to his compensation per prior offer letter dated May 29, 2024, as amended.","No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155485,"accession_number":"0001104659-25-054236","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"DarioHealth extends preferred stock lock-up to Feb 2026; amends certificates for warrant dividends","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended lock-up agreements with Series B/C preferred holders extend restrictive period until February 21, 2026.","Holders receive additional 10% of common stock underlying preferred shares for each 3-month extension.","Company filed amended certificates for Series A-1 and B-1 preferred stock to allow dividends in pre-funded warrants.","No new securities issued under certificate amendments; provides alternative form for future dividends.","Breach of lock-up before Eligibility Date forfeits right to subsequent share consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155484,"accession_number":"0001104659-25-051292","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"DarioHealth extends mandatory conversion period for Series C preferred stock from 15 to 24 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mandatory conversion period extended from 15 to 24 months for Series C, C-1, C-2 preferred stock.","Preferred holders will receive a quarterly dividend of 15% of common shares issuable upon conversion.","No new securities were issued or sold as a result of the amendment.","Amended and restated certificates of designation filed on May 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155483,"accession_number":"0001104659-25-044809","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"DarioHealth enters $32.5M credit agreement with Callodine; warrants issued","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $32.5M at closing; may draw up to $17.5M more subject to revenue thresholds and lender discretion.","Loan bears interest at Term SOFR + 7.75%, matures April 2030; secured by substantially all assets.","Issued warrants to purchase 2,114,140 shares at $0.8278; up to $2.5M loan principal convertible at $0.9933 per share.","Prior Loan and Security Agreement with Avenue terminated; proceeds used to satisfy LSA.","Financial covenants include minimum unencumbered liquid assets, total revenue, and Adjusted EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155482,"accession_number":"0001104659-25-040182","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DarioHealth shareholders approve up to 51.7M share issuance and warrant repricing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vote passed 21.4M for, 0.44M against, 0.08M abstain at special meeting on April 28, 2025.","Authorizes conversion of 25,605 Series D-3 preferred shares into 33.96M common shares from Dec 2024/Jan 2025 private placements.","Also authorizes up to 13.58M common shares as dividends on Series D-3 preferred and up to 4.18M shares for lock-up agreements with B/C preferred holders.","Warrant repricing: 584,882 warrants to Avenue at $0.7208/share; loan conversion up to $2M at $0.8650/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155481,"accession_number":"0001104659-25-036910","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"DarioHealth CFO Zvi Ben-David resigns; Chen Franco-Yehuda appointed CFO effective May 15, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zvi Ben-David resigns as CFO, Treasurer, Secretary effective May 15, 2025; departure for personal reasons, not due to any disagreement.","Chen Franco-Yehuda appointed CFO, Treasurer, Secretary same date; previously CFO of Pluri Inc. (PLUR) and former PwC auditor.","New CFO receives monthly salary of approx. $22,245 (NIS 82,000), target bonus up to 6x base salary, and 500,000 RSUs vesting over three years.","Separation agreement: Ben-David joins advisory board, receives reduced monthly payments of ~$14,266 through Dec 2025 and ~$12,982 through Oct 2027.","Employment agreement includes 90-day notice period, 6-month adjustment period on termination, and 12-month non-competition covenant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173967,"accession_number":"0001104659-25-025549","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"DarioHealth receives Nasdaq extension to Sept 15, 2025 to regain $1 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Staff granted additional 180 days until September 15, 2025 to meet Minimum Bid Price Requirement.","Must close at or above $1.00 for 10 consecutive trading days to regain compliance.","Company considering measures including a potential stock split to address the deficiency.","No assurance compliance will be achieved; failure risks delisting from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173966,"accession_number":"0001104659-25-023589","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"DarioHealth dismisses EY as auditor, appoints PwC effective March 12, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EY dismissed as independent auditor; PwC (Kesselman & Kesselman) engaged effective March 12, 2025.","No disagreements or reportable events between DarioHealth and EY in fiscal 2024 or 2023.","Company had previously consulted PwC on valuation, borrowing rates, and goodwill impairment.","EY provided a letter agreeing with the company's disclosures, filed as Exhibit 16.1.","Audit Committee of the Board approved the change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173965,"accession_number":"0001104659-25-018230","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"DarioHealth appoints healthcare industry veteran Larry Leisure to board; director Kaplan resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lawrence Leisure appointed to board effective Feb 25, 2025; brings 40 years healthcare experience.","Jon Kaplan voluntarily resigned from board on Feb 24, 2025, no disagreement with company.","Leisure co-founded Chicago Pacific Founders; his firm NearWater has consulting agreement with Dario.","Dario entered Second Amendment to Consulting Agreement with NearWater on Feb 24, 2025, $10k monthly retainer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173964,"accession_number":"0001104659-25-005237","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DarioHealth closes $25.6M private placement; targets cash flow positive by end of 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $25.6M via convertible preferred stock at conversion prices of $0.73 and $0.83; majority from existing shareholders.","Pro forma cash balance of $40.6M as of Q3 2024; aims to achieve operational cash flow positive run rate by end of 2025.","Preferred stock pays 10% quarterly stock dividend for first four quarters; conversion subject to stockholder approval.","Lock-up agreements with Series B & C preferred holders to receive up to 40% additional common shares over 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173963,"accession_number":"0001104659-25-002576","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"DarioHealth Raises ~$6.8M via Series D Convertible Preferred Private Placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 4,974 shares of Series D-2 and 1,850 shares of Series D-3 preferred at $1,000 each for ~$6.8M gross.","Conversion price initially $0.83 per share; subject to stockholder approval; auto-convert after 12 months.","Preferred stock pays 10% quarterly dividend in common shares for four quarters after issuance.","Closing expected by January 14, 2025; securities exempt from registration under Rule 506(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190936,"accession_number":"0001104659-24-129777","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"DarioHealth raises ~$18.8M via preferred stock; amends Avenue loan to extend maturity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 7,055 Series D and 11,750 Series D-1 preferred shares at $1,000 each, raising $18.8M.","Preferred stock convertible at $0.73/share, subject to stockholder approval and a 19.99% beneficial ownership blocker.","Amended Avenue loan: extended interest-only period by 6 months, conditional on revenue milestone; maturity extended to Nov 1, 2027.","Proforma cash balance of $34M as of Q3 2024; company targets profitability run-rate by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190935,"accession_number":"0001104659-24-129752","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DarioHealth stockholders elect all 7 director nominees and ratify EY as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven nominees elected: Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Jon Kaplan, and Adam K. Stern.","Each director received >15.8M votes for; broker non-votes totaled 6.67M shares.","Ratification of Kost Forer Gabbay & Kasierer (Ernst & Young) as auditor for FY2024 approved with 22.65M for, 106K against, 17.5K abstain.","Final vote tallies include preferred stock on an as-converted basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207422,"accession_number":"0001104659-24-101690","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"DarioHealth receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on Sept 16, 2024: closing bid price below $1.00 for 30 consecutive business days.","180-day compliance period granted until March 17, 2025 to regain compliance.","To cure, bid price must close at $1.00+ for 10 consecutive business days.","If not compliant, a second 180-day period may be available if other listing standards met.","Company will monitor bid price and consider options; no assurance of compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207421,"accession_number":"0001104659-24-099762","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"DarioHealth extends Series B-3 mandatory conversion period and increases dividends","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mandatory conversion period extended from 15 to 18 months from original issue date.","Dividends increased: 10% for fifth full quarter and 25% for sixth quarter from closing.","No additional securities were issued or sold as a result of the amendment.","Amendment effective September 11, 2024, approved by majority of preferred stock holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224842,"accession_number":"0001104659-24-076313","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"DarioHealth amends Series B and B-1 Preferred Stock, extends conversion period, adds dividends","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mandatory conversion period extended from 15 to 18 months from original issue date.","Series B and B-1 holders get 10% dividend for fifth full quarter, 25% for sixth quarter from closing.","No additional securities were issued or sold as a result of the amendment.","Amendments filed on June 25, 2024, effective upon filing with Delaware Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224841,"accession_number":"0001104659-24-074740","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve Twill acquisition share issuance and 3M share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1: Approved share issuance upon exercise of warrants and RSUs from Twill acquisition and warrant re-pricing; 16,262,466 for, 1,191,420 against.","Proposal 2: Approved amendment to 2020 Plan increasing share reserve by 3,000,000 shares; 14,257,236 for, 3,156,778 against.","Both proposals required majority of votes cast; passed at the 2024 Special Meeting on June 25, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224840,"accession_number":"0001104659-24-068526","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"DarioHealth appoints Steven Nelson as CCO; President Richard Anderson departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Nelson, formerly CEO of Contigo Health (Premier Inc.), named Chief Commercial Officer effective June 5, 2024.","Nelson receives $400,000 base salary, annual bonus up to $400,000 tied to GAAP revenue targets (targets redacted).","Nelson granted time-vesting option for 500,000 shares and performance options for up to 400,000 (2024) and 450,000 shares (2025-2027) vested on revenue milestones.","President Richard Anderson mutually agreed to step down; no disagreement; will stay as consultant and Advisory Board member.","Anderson's departure not related to any disagreement with company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}